B R Krause

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis
    B R Krause
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Curr Opin Investig Drugs 2:375-81. 2001
  2. ncbi Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase
    B R Krause
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Lipids 33:489-98. 1998
  3. ncbi High correlation but lack of agreement between direct high-performance gel chromatography analysis and conventional indirect methods for determining lipoprotein cholesterol
    B R Krause
    Cardiac and Vascular Diseases, Parke Davis Pharmaceutical Research Div, Warner Lambert Co, Ann Arbor, MI 48105, USA
    Clin Chem 42:1996-2001. 1996
  4. ncbi Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbits
    M E Pape
    Division of Therapeutics, Parke Davis Pharmaceutical Research Division, Ann Arbor, MI 48105, USA
    J Lipid Res 36:823-38. 1995

Collaborators

  • M E Pape
  • R B DeMattos
  • R S Newton
  • K Kieft
  • T J Rea
  • P A Schultz
  • C L Bisgaier

Detail Information

Publications4

  1. ncbi Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis
    B R Krause
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Curr Opin Investig Drugs 2:375-81. 2001
    ..Despite the complexities and uncertainties, drugs should be developed which impact all of the above steps, and short-term endpoints need to be defined for a cautious, systematic approach to clinical evaluation...
  2. ncbi Lipid-lowering effects of WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase
    B R Krause
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    Lipids 33:489-98. 1998
    ....
  3. ncbi High correlation but lack of agreement between direct high-performance gel chromatography analysis and conventional indirect methods for determining lipoprotein cholesterol
    B R Krause
    Cardiac and Vascular Diseases, Parke Davis Pharmaceutical Research Div, Warner Lambert Co, Ann Arbor, MI 48105, USA
    Clin Chem 42:1996-2001. 1996
    ..In addition, both Bland-Altman plots and concordance correlation analyses indicated lack of agreement between the methods' results in the majority of patients' subgroups...
  4. ncbi Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbits
    M E Pape
    Division of Therapeutics, Parke Davis Pharmaceutical Research Division, Ann Arbor, MI 48105, USA
    J Lipid Res 36:823-38. 1995
    ..These data indicate that ACAT mRNA14b levels increase in a tissue specific manner in response to dietary fat and cholesterol...